Genetically encoded probes powerfully and non-invasively target specific tissues, cells, and subcellular locations. iRFP, a novel near-infrared fluorescent protein with low quantum yield whose absorption and fluorescence maxima are located at wavelengths longer than the Q-band of hemoglobin absorption, is ideal for PAT. Here, we report on an in vitro comparison of iRFP with other far-red fluorescent proteins, and its use in imaging a mouse tumor xenograft model. In an in vivo experiment, we stably transfected iRFP into MTLn3 adenocarcinoma cells and injected them into the mammary fat pad of female SCID/NCr mice, then imaged the resulting tumors two and three weeks post injection. The contrast increase from the protein expression was high enough to clearly separate the tumor region from the rest of the animal.
Introduction:
Genetically encoded fluorescent proteins (FPs) can provide endogenous contrast for various imaging applications since they can be produced by living cells and tissues. The application of conventional FPs for PA imaging of mammals has been a problem due to high hemoglobin absorption below 650 nm 1 . iRFP has a very high extinction coefficient of 105,000 M -1 cm -1 , a low fluorescence quantum yield of 6%, and its absorption spectra lies in the near-infrared window, all beneficial properties for PA imaging 2 . iRFP, being a fluorescent protein, also provides additional options for signal analysis and quantification through fluorescence.
We wante We can waveleng signal rati performed an s the iRFP pr n a SCID/NCr ter the inject ent full ring t re the relativ e 1 that blo due to its hi f the tested F Until recently, excitation of FPs was limited to the blue, green, and red spectral regions where hemoglobin absorption is high. Because of this, their use for whole-body imaging has been challenging. By combining an iRFP probe with the deep imaging capabilities of PACT this study demonstrates the capability of deep tissue imaging of fluorescent proteins.
